Mirabegron has longer treatment persistence than antimuscarinics: Real‐world data from a Korean national cohort database-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Mirabegron has longer treatment persistence than antimuscarinics: Real‐world data from a Korean national cohort database

Published:2021-09-06 Issue:8 Volume:40 Page:1972-1980
ISSN:0733-2467
Container-title:Neurourology and Urodynamics
language:en
Short-container-title:Neurourol Urodyn

Author:

Lee Kyu‐Sung¹^ORCID,Park Hyejeong¹,Kang Danbee¹,Byun Hye J.²,Foo Chee Y.³^ORCID,Hadi Farid A.⁴,Kim Soyoung⁴,Cho Juhee⁵^ORCID

Affiliation:

1. Department of Urology. Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea

2. Department of Urology, Dongsan Medical Center Keimyung University School of Medicine Daegu South Korea

3. Real World Evidence IQVIA Petaling Jaya Malaysia

4. Medical Affairs Astellas Pharma Singapore Pte. Ltd Singapore Singapore

5. Department of Clinical Research Design and Evaluation, SAIHST Sungkyunkwan University Seoul South Korea

Funder

Astellas Pharma

Publisher

Wiley

Subject

Urology,Neurology (clinical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/nau.24776

Reference28 articles.

1. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

2. Prospective, Randomized, Double-Blind Study of the Efficacy and Tolerability of the Extended-Release Formulations of Oxybutynin and Tolterodine for Overactive Bladder: Results of the OPERA Trial

3. The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis

4. Anticholinergic Drug Exposure and the Risk of Dementia

5. Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictors of non-persistence in women with overactive bladder syndrome;Scientific Reports;2024-03-29

2. Treatment Patterns with Mirabegron and Antimuscarinics for Overactive Bladder: A Prospective, Registry Study in Taiwan and South Korea (FAITH);Advances in Therapy;2024-03-02

3. Persistence of overactive bladder pharmacological treatment in women as reflected from large‐scale real‐world data of prescription claims: A retrospective cohort study;Neurourology and Urodynamics;2023-07-03

4. A Randomized, Double-Blind, Placebo-Controlled, Bridging Study to Evaluate the Efficacy and Safety of Vibegron in Treating Korean Patients With Overactive Bladder;International Neurourology Journal;2023-06-30

5. Overactive bladder: An underestimated troublesome problem in women;Taiwanese Journal of Obstetrics and Gynecology;2022-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3